Community Magazine
It was a delight for me to be asked by Andrew Schorr on behalf of Patient Power to be interviewed in order to share the patient's perspective on how to use all the news from iwCLL 2013 in Cologne, Germany.
I particularly like the way he took the trouble to highlight some of my points with the superimposed text.
Over the next weeks, I will have many more informative interviews to post with Drs. Kipps, Kay, Furman, Hallek and others, but I thought I would first let you hear my counsel on how to best deal with your doctor appointments.
In the meantime, please let me know what you think of my suggestions and please add your own tips and advice to the communal discussion.
iwCLL 2013 Cologne, Germany
I particularly like the way he took the trouble to highlight some of my points with the superimposed text.
Over the next weeks, I will have many more informative interviews to post with Drs. Kipps, Kay, Furman, Hallek and others, but I thought I would first let you hear my counsel on how to best deal with your doctor appointments.
In the meantime, please let me know what you think of my suggestions and please add your own tips and advice to the communal discussion.
iwCLL 2013 Cologne, Germany
Author's Latest Articles
-
ASH 2020: Dr. Anthony Mato on LOXO-305 A Next Generation Highly Selective Non-Covalent BTK Inhibitor.
-
ASH 2020: Dr. Arnon Nagler on Safety and Efficacy of CD19-CAR T Cells in Richter’s Transformation After Targeted Therapy for Chronic Lymphocytic Leukemia (CLL)
-
EHA 2021: Dr. Anthony Mato on Pirtobrutinib (LOXO-305) for Richter’s Transformation in Chronic Lymphocytic Leukemia (CLL)
-
ASH 2020: Dr. Peter Hillmen on the CLARITY Trial of Ibrutinib Plus Venetoclax for Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)